Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Tosedostat (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2018 Status changed from active, no longer recruiting to discontinued.
- 20 Feb 2018 Planned End Date changed from 31 Mar 2019 to 9 Nov 2018.
- 04 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Jan 2018.